In an ongoing trial evaluating MEK inhibitor selumetinib in combination with olaparib in primarily KRAS-mutated tumours, 2 of 14 patients had a confirmed partial response, and the combination was safe and tolerable [65]. The gene discussed is KRAS; the disease is neoplasm.